Swiss National Bank - ARROWHEAD PHARMACEUTICALS IN ownership

ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 161 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.1%.

Quarter-by-quarter ownership
Swiss National Bank ownership history of ARROWHEAD PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$6,000,071
-24.9%
223,300
-0.3%
0.01%0.0%
Q2 2023$7,987,840
+44.7%
224,000
+3.1%
0.01%
+25.0%
Q1 2023$5,519,420
-44.0%
217,300
-10.5%
0.00%
-42.9%
Q4 2022$9,847,968
+25.1%
242,800
+1.9%
0.01%
+16.7%
Q3 2022$7,873,000
-5.3%
238,200
+0.9%
0.01%0.0%
Q2 2022$8,313,000
-23.0%
236,100
+0.6%
0.01%0.0%
Q1 2022$10,798,000
-25.3%
234,800
+7.7%
0.01%
-33.3%
Q4 2021$14,453,000
+6.0%
218,000
-0.2%
0.01%0.0%
Q3 2021$13,641,000
-24.2%
218,500
+0.6%
0.01%
-18.2%
Q2 2021$17,997,000
+21.7%
217,300
-2.6%
0.01%
+10.0%
Q1 2021$14,787,000
-12.3%
223,000
+1.5%
0.01%
-16.7%
Q4 2020$16,858,000
+78.7%
219,700
+0.3%
0.01%
+71.4%
Q3 2020$9,434,000
+1.4%
219,100
+1.7%
0.01%
-12.5%
Q2 2020$9,307,000
+93.6%
215,500
+29.0%
0.01%
+60.0%
Q1 2020$4,807,000
-53.8%
167,100
+1.8%
0.01%
-54.5%
Q4 2019$10,415,000
+130.1%
164,200
+2.2%
0.01%
+120.0%
Q3 2019$4,526,000
+8.2%
160,600
+1.8%
0.01%0.0%
Q2 2019$4,182,000
+57.8%
157,800
+9.3%
0.01%
+66.7%
Q1 2019$2,650,000
+52.3%
144,400
+3.1%
0.00%
+50.0%
Q4 2018$1,740,000
-33.3%
140,100
+3.0%
0.00%
-33.3%
Q3 2018$2,607,000
+40.9%
136,0000.0%0.00%
+50.0%
Q2 2018$1,850,000
+994.7%
136,000
+48.8%
0.00%
Q1 2017$169,000
+19.0%
91,4000.0%0.00%
Q4 2016$142,000
-78.9%
91,4000.0%0.00%
-100.0%
Q3 2016$672,000
+38.3%
91,4000.0%0.00%0.0%
Q2 2016$486,00091,4000.00%
Other shareholders
ARROWHEAD PHARMACEUTICALS IN shareholders Q4 2018
NameSharesValueWeighting ↓
Western Financial Corp/CA 820,320$33,272,17921.56%
Aquilo Capital Management, LLC 1,103,515$44,758,56816.81%
M28 Capital Management LP 143,900$5,836,5845.56%
WEALTH EFFECTS LLC 155,620$6,311,9513.60%
Evolutionary Tree Capital Management, LLC 92,095$3,735,3733.59%
Privium Fund Management B.V. 221,015$8,867,1223.36%
JOHNSON & JOHNSON 247,598$10,0432.92%
COMMODORE CAPITAL LP 462,111$18,7432.82%
Avidity Partners Management LP 1,375,000$55,770,0001.21%
Capital Impact Advisors, LLC 26,853$1,089,1581.06%
View complete list of ARROWHEAD PHARMACEUTICALS IN shareholders